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Abstract
© 2018 Medical Education. All rights reserved. Mild asthma is characterized by infrequent and
slight clinical manifestations and, therefore, is paid lack of attention both from patients and
physicians. Physicians tend to underestimate risk of severe exacerbations including asthmatic
status in patients with mild asthma. Patients with mild asthma are often poorly adherent to
treatment. Also, certain difficulties are related to timely and correct diagnosis and the choice of
the optimal treatment by primary care physicians who are first physicians encountering such
patients. The paradoxus of asthma and use of short-acting β2-agonists (SABA) to treat chronic
airway  inflammation  lead  to  excessive  dependence  on  rescue  inhalers  and  insufficient
adherence to maintenance anti-inflammatory therapy. This could trigger acute exacerbations
and even fatal outcomes in patients with mild asthma. Therefore, SABA monotherapy has to be
limited. Easy-to-use questionnaires, algorithms and treatment protocols accessible for primary
care physicians could improve detection of mild asthma. Favorable results of clinical trials on as-
needed use of budesonide/formoterol Turbuhaler®could change the management paradigm for




As-needed use of inhaled corticosteroid/long-acting β2-agonist combination,
Budesonide/formoterol, Inhaled corticosteroids, Mild asthma, Short-acting β2-agonists
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